– Sir Andrew Dillon, NICE chief executive
During the consultation on the draft guidance Janssen, the manufacturer of the drug, submitted further information for the committee to consider.
This included a revised patient access scheme which involves providing the drug to the NHS at a discounted price, further information on which patients would benefit most and clarification on how many patients could receive the drug.
These factors enabled the committee to revise its preliminary recommendation and now recommend the drug for use on the NHS.
The National Institute for Health and Clinical Excellence (Nice) has revised its recommendations on a drug to treat advanced prostate cancer. The institute now says Abirateron, marketed as Zytiga, should be given to patients on the NHS.